The day is coming when Humira (adalimumab) will no longer dominate the biggest-selling drug charts, but not next year. AbbVie’s powerhouse again tops sales forecasts, with nearly US$20 billion in expected sales in 2021 (Table 1). To put Humira’s recent dominance of the industry into context, from its launch in 2003 until the end of June 2020, the anti-TNF monoclonal antibody (mAb) generated $165.8 billion in cumulative sales. So, this year, it has snatched the crown for the industry’s most successful drug from Lipitor (atorvastatin), a cholesterol-lowering drug that racked up ~$160 billion in full-year sales in 23 years on the market.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD